Article Text
DTB select
Safety update: dupilumab and ocular adverse reactions
Abstract
Overview of: Medicines and Healthcare products Regulatory Agency. Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management. Drug Safety Update 2022;16(4): 1.
- Health Care Quality, Access, and Evaluation
- Drug-Related Side Effects and Adverse Reactions
Statistics from Altmetric.com
Footnotes
Contributors DTB Team.
Provenance and peer review Commissioned; internally peer reviewed.